Standalone and Consolidated Unaudited Financial Results for Q1FY26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Makers Laboratories reported its Q1FY26 results on both standalone and consolidated basis, reviewed by auditor N V C & Associates LLP (formerly Natvarlal Vepari & Co.) with a clean, unqualified review report. On a standalone basis, revenue from operations rose to ₹1,372.68 lacs from ₹1,228.95 lacs in Q1FY25 (about 11.7% growth), but the company stayed in the red with a loss after tax of ₹123.54 lacs, though narrower than the ₹197.10 lacs loss a year ago. On a consolidated basis (which includes 45.48%-owned subsidiary Resonance Specialties Ltd), revenue from operations was ₹2,959.17 lacs versus ₹3,390.24 lacs in Q1FY25, a decline of roughly 12.7%. Despite the revenue dip, the company turned profitable at the consolidated level with profit after tax (after non-controlling interest) of about ₹43.67 lacs, helped by subsidiary contribution. Consolidated profit before tax was ₹158.08 lacs after booking an exceptional expense of ₹52.65 lacs.
Mixed picture for shareholders — the standalone pharma business is still loss-making but losses are shrinking, while consolidated profitability has returned largely on the back of the chemical subsidiary. The ₹52.65 lacs exceptional charge and a 12.7% drop in consolidated revenue are points to watch; near-term stock reaction may be subdued until revenue stabilises and standalone turns profitable.